Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
Top Page
Werewolf Therapeutics
(NASDAQ:HOWL)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.84
▲(7.82% Upside)
Action:ReiteratedDate:03/27/26
The score is held down primarily by weak financial performance—large ongoing losses, worsening cash burn, and deteriorating/absent recent revenue—alongside negative corporate events (major restructuring and Nasdaq bid-price deficiency). Technical indicators provide some offsetting support with improving momentum, but valuation is constrained by continued unprofitability.
Positive Factors
Proprietary targeted immunotherapy platform
Werewolf’s PREDATOR/INDUKINE/INDUCER masking and protease-linker technology is a structural competitive asset. A platform that enables tumor‑restricted activation can widen therapeutic windows, support multiple programs and modalities, and increase licensing and partnership optionality over time.
Negative Factors
Large, persistent cash burn and losses
Consistent, substantial negative operating cash flow with no recent revenue is a durable weak spot: it forces reliance on financing or asset dispositions, strains balance sheet metrics, and raises execution risk for development programs absent steady partner funding or a liquidity event.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary targeted immunotherapy platform
Werewolf’s PREDATOR/INDUKINE/INDUCER masking and protease-linker technology is a structural competitive asset. A platform that enables tumor‑restricted activation can widen therapeutic windows, support multiple programs and modalities, and increase licensing and partnership optionality over time.
Read all positive factors
Werewolf Therapeutics (HOWL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$37.90M
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)1.61
Revenue Growth-100.00%
EPS Growth-8.30%
CountryUS
Employees46
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding48,540,200
10 Day Avg. Volume1,746,006
30 Day Avg. Volume1,221,642
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.18
Price to Sales (P/S)0.00
P/FCF Ratio-0.48
Enterprise Value/Market Cap-0.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.76
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$7.00Price Target Upside797.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.37
Revenue Forecast (FY)N/A
Werewolf Therapeutics Business Overview & Revenue Model
Company Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated m...
How the Company Makes Money
Werewolf Therapeutics does not sell approved products; as a clinical-stage biotech, it has historically generated revenue primarily through collaboration and licensing arrangements rather than commercial drug sales. Key revenue streams typically i...
Werewolf Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 1.89M | 19.94M | 16.40M | 0.00 |
| Gross Profit | 0.00 | 71.00K | 18.18M | 13.89M | 0.00 |
| EBITDA | 0.00 | -64.05M | -32.47M | -51.30M | -49.87M |
| Net Income | -60.82M | -70.52M | -37.37M | -53.81M | -49.98M |
Balance Sheet | |||||
| Total Assets | 69.40M | 126.93M | 174.83M | 160.25M | 179.25M |
| Cash, Cash Equivalents and Short-Term Investments | 57.95M | 111.00M | 134.34M | 129.31M | 157.53M |
| Total Debt | 9.44M | 37.09M | 51.92M | 14.68M | 15.66M |
| Total Liabilities | 44.59M | 53.54M | 63.46M | 37.91M | 26.46M |
| Stockholders Equity | 24.80M | 73.39M | 111.37M | 122.34M | 152.79M |
Cash Flow | |||||
| Free Cash Flow | -60.29M | -56.44M | -33.38M | -44.21M | -43.37M |
| Operating Cash Flow | -60.29M | -56.19M | -32.61M | -40.60M | -42.88M |
| Investing Cash Flow | 0.00 | -254.00K | -769.00K | -3.61M | -498.00K |
| Financing Cash Flow | 6.03M | 13.08M | 58.43M | 15.91M | 109.43M |
Werewolf Therapeutics Technical Analysis
Neutral
0.78
Price Trends
0.69
Positive
0.79
Negative
1.11
Negative
Market Momentum
0.04
Positive
52.77
Neutral
36.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOWL, the sentiment is Neutral. The current price of 0.78 is above the 20-day moving average (MA) of 0.75, above the 50-day MA of 0.69, and below the 200-day MA of 1.11, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 52.77 is Neutral, neither overbought nor oversold. The STOCH value of 36.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HOWL.
Werewolf Therapeutics Risk Analysis
Werewolf Therapeutics disclosed 87 risk factors in its most recent earnings report. Werewolf Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Werewolf Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $72.42M | -2.03 | 138.71% | ― | ― | -9.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $34.44M | -2.65 | -76.78% | ― | -38.81% | -76.96% | |
47 Neutral | $223.77M | -2.32 | -162.49% | ― | ― | 5.51% | |
45 Neutral | $37.90M | -0.48 | -122.43% | ― | -100.00% | -8.30% | |
45 Neutral | $112.99M | -2.97 | -73.11% | ― | ― | 63.31% |
* Healthcare Sector Average
HOWL
Werewolf Therapeutics
0.78
-0.25
-24.27%
CRVO
CervoMed
3.72
-5.76
-60.76%
NRXP
NRX Pharmaceuticals
2.19
0.16
7.88%
KLRS
Kalaris Therapeutics
5.39
-3.21
-37.33%
COEP
Coeptis Therapeutics Holdings
10.68
1.30
13.86%
CAMP
CAMP4 Therapeutics Corporation
4.31
0.02
0.47%
Werewolf Therapeutics Corporate Events
Business Operations and StrategyM&A Transactions
Werewolf Therapeutics Begins Strategic Alternatives Review Process
Neutral
Feb 24, 2026
On February 24, 2026, Werewolf Therapeutics announced it is exploring a full range of strategic alternatives to advance its immunotherapy platform and pipeline and to maximize stockholder value. The company has retained Piper Sandler Co. as its e...
Business Operations and StrategyExecutive/Board Changes
Werewolf Therapeutics Announces Major Workforce and Leadership Restructuring
Negative
Feb 13, 2026
On February 9, 2026, Werewolf Therapeutics’ board approved a major reduction in force cutting 64% of its workforce, a cost-cutting move expected to be largely completed by February 13, 2026 and to result in an estimated one-time severance-re...
Delistings and Listing ChangesRegulatory Filings and Compliance
Werewolf Therapeutics Receives Nasdaq Minimum Bid Price Notice
Negative
Feb 6, 2026
On February 4, 2026, Werewolf Therapeutics, Inc. disclosed that it had received a Nasdaq deficiency notice after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting its Nasdaq Global Select Market li...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.